Video

Dr. Roger Li on CG0070 combined with pembrolizumab in NMIBC unresponsive to BCG

Author(s):

Urology Times staff
Conference|ASCO Annual Meeting

“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.

In this video, Roger Li, MD, discusses the 2022 ASCO Annual Meeting study, “CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).” Li is a genitourinary oncologist at Moffitt Cancer Center in Tampa, Florida.

Related Videos
Sarah Razavi, MD, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Woman talking with a doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Related Content
Welcome to fabulous Las vegas Nevada sign with blur strip road b | Image Credit: © littlestocker - stock.adobe.com
May 5th 2025

AUA 2025 recap: Urologic oncology trials in progress

Hannah Clarke
Take a look through some of the notable studies that were spotlighted during this year’s meeting.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC
May 2nd 2025

TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC

Hannah Clarke
Data showed an overall CR rate of 82.4%.
Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
April 30th 2025

Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

Amy M. Pearlman, MD Ryan Terlecki, MD
A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
April 30th 2025

TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

Hannah Clarke
Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Published: April 29th 2025 | Updated: April 29th 2025

Ultra-low PSA responses are more prevalent with darolutamide plus ADT

Benjamin P. Saylor
The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
© 2025 MJH Life Sciences

All rights reserved.